Extracellular vesicle-derived miR-144 as a novel mechanism for chronic intermittent hypoxia-induced endothelial dysfunction
Quick Facts
- Publication title: Extracellular vesicle-derived miR-144 as a novel mechanism for chronic intermittent hypoxia-induced endothelial dysfunction
- Journal: Theranostics
- Year: 2022
- DOI: 10.7150/thno.69035
- PMID/PMCID: 35673562; PMC9169375
Research overview
Additionally, we identified that erythrocytes were the primary cellular source of miR-144-enriched serum-derived extracellular vesicles and that erythrocyte-derived extracellular vesicles were largely responsible for chronic intermittent hypoxia-impaired endothelial function. Conclusion: The results expand the scope of blood-borne substances involved in vascular homeostasis and suggest that anti-miR-144-loaded extracellular vesicles may represent a promising therapeutic approach against obstructive sleep apnea or chronic intermittent hypoxia-associated endothelial dysfunction.
Key findings
Rationale: Extracellular vesicles (EVs) play a significant role in cell-cell communication.
However, whether and how extracellular vesicles are involved in chronic intermittent hypoxia-induced endothelial dysfunction is unknown.
Methods: Comparative transcriptomics analysis and miRNA screening were used to identify the possible pathways or target molecules mediating chronic intermittent hypoxia-induced endothelial function.
Serum- or erythrocyte-derived EVs were isolated through ultracentrifugation plus filtration.
Echo Biotech Role
Echo Biotech contributed EV characterization.
Related platforms: Exoomics®
Related services and capabilities: EV Basic Characterization (TEM/NTA/WB)
References
Original publication: Extracellular vesicle-derived miR-144 as a novel mechanism for chronic intermittent hypoxia-induced endothelial dysfunction Theranostics. 2022. DOI: 10.7150/thno.69035. PMID/PMCID: 35673562; PMC9169375.